Serum iron parameters
| . | Pre . | Days of rhEpo treatment . | ||||
|---|---|---|---|---|---|---|
| 0 . | 2 . | 4 . | 6 . | 8 . | 28 . | |
| sTfR (nmol.L−1) | 16.6 ± 4.0 | 17.9 ± 5.8 | 19.3 ± 7.2* | 22.7 ± 7.8* | 25.7 ± 6.5* | 30.1 ± 9.0* |
| Ferritin (μg.L−1) | 74.9 ± 65.4 | 74.7 ± 76.6 | 60.1 ± 64.7* | 46.4 ± 50.0* | 36.6 ± 36.2* | 36.5 ± 29.4* |
| Transferrin (g.L−1) | 2.7 ± 0.1 | 2.7 ± 0.2 | 2.7 ± 0.3 | 2.8 ± 0.3 | 2.9 ± 0.3 | 2.9 ± 0.3 |
| Serum iron (μmol.L−1) | 18.1 ± 5.0 | 12.4 ± 3.7* | 9.4 ± 5.7* | 8.3 ± 3.1* | 7.2 ± 3.3* | 10.5 ± 4.5* |
| Iron saturation of transferrin (%) | 27 ± 8 | 19 ± 6 | 14 ± 9 | 12 ± 5* | 10 ± 5* | 15 ± 6* |
| Ceruloplasmin (g.L−1) | 0.26 ± 0.03 | 0.27 ± 0.06 | 0.28 ± 0.06 | 0.29 ± 0.06 | 0.29 ± 0.06 | 0.25 ± 0.03 |
| . | Pre . | Days of rhEpo treatment . | ||||
|---|---|---|---|---|---|---|
| 0 . | 2 . | 4 . | 6 . | 8 . | 28 . | |
| sTfR (nmol.L−1) | 16.6 ± 4.0 | 17.9 ± 5.8 | 19.3 ± 7.2* | 22.7 ± 7.8* | 25.7 ± 6.5* | 30.1 ± 9.0* |
| Ferritin (μg.L−1) | 74.9 ± 65.4 | 74.7 ± 76.6 | 60.1 ± 64.7* | 46.4 ± 50.0* | 36.6 ± 36.2* | 36.5 ± 29.4* |
| Transferrin (g.L−1) | 2.7 ± 0.1 | 2.7 ± 0.2 | 2.7 ± 0.3 | 2.8 ± 0.3 | 2.9 ± 0.3 | 2.9 ± 0.3 |
| Serum iron (μmol.L−1) | 18.1 ± 5.0 | 12.4 ± 3.7* | 9.4 ± 5.7* | 8.3 ± 3.1* | 7.2 ± 3.3* | 10.5 ± 4.5* |
| Iron saturation of transferrin (%) | 27 ± 8 | 19 ± 6 | 14 ± 9 | 12 ± 5* | 10 ± 5* | 15 ± 6* |
| Ceruloplasmin (g.L−1) | 0.26 ± 0.03 | 0.27 ± 0.06 | 0.28 ± 0.06 | 0.29 ± 0.06 | 0.29 ± 0.06 | 0.25 ± 0.03 |
Mean values (± SD) for 8 participants. Venous blood samples were obtained before (Pre) and on several occasions during treatment with recombinant human Epo (rhEpo). The statistical differences from pre-rhEpo values were calculated using the Wilcoxon test.
sTfR indicates soluble transferrin receptor.
P < .05.